Product
NNC0194-0499
6 clinical trials
7 indications
Indication
Healthy Control ParticipantsIndication
Healthy VolunteersIndication
Liver ImpairmentIndication
Non-alcoholic SteatohepatitisIndication
Non-alcoholic Steatohepatitis (NASH)Indication
Non-alcoholic Fatty Liver DiseaseIndication
Alcohol-related Liver DiseaseClinical trial
Investigation of Pharmacokinetics, Safety and Tolerability of a Single Subcutaneous Dose of NNC0194-0499 in Participants With Various Degrees of Hepatic Impairment and Normal Hepatic FunctionStatus: Recruiting, Estimated PCD: 2024-08-17
Clinical trial
Investigation of the Effect of NNC0194-0499 on Pharmacokinetics of a Combined Oral Contraceptive (Ethinylestradiol and Levonorgestrel) in Females of Non-childbearing Potential. .Status: Recruiting, Estimated PCD: 2024-08-14
Clinical trial
Investigation of Pharmacokinetics Following Administration of NNC0194-0499 and Semaglutide as Co-formulation Versus Separate Injections in Healthy ParticipantsStatus: Completed, Estimated PCD: 2024-01-05
Clinical trial
Investigation of Pharmacokinetics, Safety and Tolerability of a Single Subcutaneous Dose of NNC0194-0499 in Participants With Various Degrees of Renal Impairment and Normal Renal FunctionStatus: Completed, Estimated PCD: 2023-11-10
Clinical trial
Investigation of Pharmacokinetic Properties of Single Subcutaneous Doses of NNC0194-0499 in Chinese MalesStatus: Completed, Estimated PCD: 2023-06-13
Clinical trial
Effects of NNC0194-0499 Alone and in Combination With Semaglutide, of Semaglutide Alone, and of Cagrilintide Alone and in Combination With Semaglutide on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseStatus: Recruiting, Estimated PCD: 2025-06-18